Sleep is a biological imperative, not a lifestyle preference. Every species we have studied — from fruit flies to humans — sleeps, and every species we have studied dies if we deprive it of sleep long enough. The brain in particular does work during sleep that it cannot do while awake. The clinical implication for longevity psychiatry is that sleep is not the soft variable in a wellness portfolio; it is the foundational substrate on which cognitive aging depends. Patients who do not sleep well are not optimizing one of many factors. They are degrading the substrate of everything else.
The glymphatic system, characterized by Nedergaard and colleagues beginning in 2012, is the most important sleep-related discovery in recent neuroscience. The glymphatic system is the brain's analogue of the lymphatic system that the rest of the body uses to clear metabolic waste. During sleep, particularly during slow-wave sleep, the interstitial space between brain cells expands by approximately 60%, and cerebrospinal fluid is pumped through the brain tissue, washing out the metabolic byproducts that accumulate during waking activity. Among the most clinically relevant byproducts cleared during this process is beta-amyloid — the protein whose accumulation is implicated in Alzheimer's disease.
The clinical implication is direct. Chronic insufficient sleep produces an accumulating clearance deficit. A single night of poor sleep elevates measured amyloid in cerebrospinal fluid. Years of chronic sleep insufficiency may compound into the amyloid burden that characterizes preclinical Alzheimer's pathology. The studies are observational and the causal direction is debated — sleep disorders are also caused by emerging dementia — but the directionality of the evidence supports treating chronic insufficient sleep as a contributor to neurodegenerative risk, not as a symptom to be tolerated.
Slow-wave sleep specifically is the architecture during which glymphatic clearance peaks. This matters because slow-wave sleep is the architectural component that diminishes most reliably with aging. The forty-year-old typically gets considerably more slow-wave sleep than the seventy-year-old, even when total sleep duration is similar. The clinical question becomes not just "how long do you sleep" but "how much slow-wave sleep are you getting" — and the interventions that preserve or enhance slow-wave sleep become longevity-psychiatry interventions in their own right.
Sleep efficiency — the percentage of time in bed actually spent sleeping — matters more than duration alone. The patient who is in bed for nine hours but sleeps fragmented for six is not equivalent to the patient who is in bed for seven hours and sleeps efficiently for six and a half. Fragmentation interrupts the architecture; the patient cycles into and out of the slow-wave and REM stages incompletely, producing the cognitive and mood consequences of insufficient sleep even when total duration looks adequate on paper.
The dose-response for cognitive protection: roughly seven to nine hours per night for most adults, with consolidation rather than fragmentation. The U-shaped mortality curve — short sleepers do worse, long sleepers also do worse — applies to cognition as well, though the long-sleep tail is more likely confounded by underlying illness than truly causal. The clinical target for most adults in the longevity-psychiatry frame is consistent, consolidated, seven-to-nine-hour sleep at consistent times, with adequate architecture verified when in doubt.
The clinical implication is that sleep is primary brain medicine. Every patient in the acceleration window deserves an actual sleep assessment — not just the typical "how is your sleep?" check-box, but a real workup that surfaces apnea, insomnia, circadian disruption, fragmentation, architecture changes, and medication effects on sleep. Patients who do this work are buying their future cognition. Patients who do not are degrading the substrate that the rest of the longevity-psychiatry interventions depend on.